For Research Use Only
BPC-157 / TB-500 Blend 10mg Pen is supplied exclusively for in vitro laboratory research. Not for human or veterinary administration. Not an injection device for clinical or personal use.
BPC-157 / TB-500 Blend 10mg Pen — Co-Formulated Research Peptide Dispensing Format
The BPC-157 / TB-500 Blend 10mg Pen is a pen-format research preparation containing 5mg BPC-157 and 5mg TB-500 (Ac-LKKTETQ) in a pre-loaded cartridge for use with the AbsoluteBioLab Reusable Metal Peptide Pen v3 dispensing device. The compound chemistry, analytical specification, and research context for each component are documented on the canonical vial product pages: BPC-157 10mg and TB-500 10mg. Batch-specific analytical documentation is available through the AbsoluteBioLab CoA Portal.
This pen format does not imply synergistic activity, complementary mechanisms, or a recommended research protocol. BPC-157 and TB-500 have separate published evidence bases and distinct mechanisms of action. No direct evidence exists for the exact co-formulated blend in the published literature — researchers should treat this as a research convenience format and design experiments accordingly.
Format Specification
| Attribute | Specification | Notes |
|---|---|---|
| Format | Pen cartridge — research dispensing format | Pre-loaded cartridge for use with Reusable Metal Peptide Pen v3 |
| Component 1 | BPC-157 5mg (CAS 137525-51-0) | Compound-level CoA available; verify against batch documentation |
| Component 2 | TB-500 5mg — Ac-LKKTETQ (CAS 77591-33-4) | Compound-level CoA available; verify against batch documentation. TB-500 ≠ thymosin beta-4 (CAS 61512-21-8) |
| Purity (RP-HPLC) | ≥99.0% each component | Compound-level CoA; verify against batch documentation |
| Identity (ESI-MS) | Both components confirmed | Compound-level CoA; verify against batch documentation |
| Compatible Device | Reusable Metal Peptide Pen v3 | Device page |
| Intended Use | Laboratory research dispensing | Research use only; not for human or veterinary administration |
Research Context
BPC-157 and TB-500 are distinct research compounds with separate published evidence bases. For the full research context, analytical specification, and scientific references for each component, refer to the canonical vial product pages: BPC-157 10mg and TB-500 10mg. No direct published evidence exists for the specific co-formulated blend — researchers should design experiments with appropriate controls for each component.
Batch Documentation
Compound-level CoA documentation (RP-HPLC purity, ESI-MS identity for both components) is available via the AbsoluteBioLab CoA Portal. A compound-level CoA documents the peptide chemistry. It does not constitute a finished-format batch record, mechanical graduation verification, or cartridge integrity certificate — these are separate device-level documents. Researchers requiring finished-format device documentation should contact AbsoluteBioLab directly.
Frequently Asked Questions
Is TB-500 the same as thymosin beta-4?
No. TB-500 (Ac-LKKTETQ, CAS 77591-33-4) is a synthetic heptapeptide corresponding to residues 17–23 of thymosin beta-4 (Tβ4, CAS 61512-21-8). They are distinct molecular entities. Refer to the TB-500 10mg vial page for the full identity documentation.
Does this blend have published evidence for the co-formulation?
No direct published evidence exists for the specific BPC-157 / TB-500 co-formulated blend. BPC-157 and TB-500 have separate published evidence bases. Researchers should design experiments with appropriate controls for each component and should not assume synergistic or additive effects without independent experimental evidence.
Where can I access the Certificate of Analysis?
Batch-specific CoA documents are available via the AbsoluteBioLab CoA Portal.
Reviews
There are no reviews yet.